Evaluation of Clinical Outcomes of Selective Versus Nonselective Beta-Blockers Among Patients With Heart Failure With Reduced Ejection Fraction Receiving Sacubitril/Valsartan. (PubMed, Ann Pharmacother) - Oct 21, 2026 - "Our results suggest that carvedilol may be associated with a higher risk of the composite endpoint, health care utilization, and adverse events but lower all-cause mortality compared with metoprolol or bisoprolol in patients with HFrEF taking sacubitril/valsartan."
Clinical data • Journal • Cardiovascular • Chronic Kidney Disease • Heart Failure • Hypotension • Nephrology • Renal Disease
|
|
Kazuhiko Kido; Khalid M Kamal; L Raymond Guo; Leonie Adjeroh; Sijin Wen; Sudarshan Balla
|